Moderna (NASDAQ:MRNA) Price Target Lowered to $96.00 at UBS Group

Moderna (NASDAQ:MRNA) had its price target trimmed by UBS Group from $108.00 to $96.00 in a research note published on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts have also recently issued research reports about the stock. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research note on Monday, November 18th. Jefferies Financial Group dropped their price target on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Tuesday, October 15th. Argus lowered Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Berenberg Bank initiated coverage on Moderna in a research report on Tuesday, November 19th. They set a “hold” rating and a $42.00 target price on the stock. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research report on Thursday, September 19th. Four analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $78.83.

Moderna Trading Down 9.2 %

Moderna stock opened at $43.17 on Wednesday. The business has a 50-day simple moving average of $43.22 and a two-hundred day simple moving average of $70.88. Moderna has a 52-week low of $35.80 and a 52-week high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The company has a market cap of $16.61 billion, a P/E ratio of -7.42 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the previous year, the business earned ($1.39) earnings per share. The business’s revenue was up 3.8% on a year-over-year basis. Analysts predict that Moderna will post -9.3 EPS for the current year.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Axiom Advisory LLC increased its holdings in shares of Moderna by 1.6% during the 3rd quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock valued at $847,000 after purchasing an additional 198 shares in the last quarter. Redwood Wealth Management Group LLC raised its position in Moderna by 6.9% during the second quarter. Redwood Wealth Management Group LLC now owns 3,342 shares of the company’s stock worth $397,000 after acquiring an additional 215 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Moderna in the second quarter valued at about $26,000. Arkadios Wealth Advisors raised its position in shares of Moderna by 2.2% during the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after purchasing an additional 243 shares during the last quarter. Finally, Knuff & Co LLC lifted its stake in Moderna by 5.4% in the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after buying an additional 244 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.